Trending: Bristol Myers Squibb Buying Mirati Therapeutics
09 Outubro 2023 - 11:30AM
Dow Jones News
10:00 ET -- Bristol Myers Squibb is one of the most mentioned
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. Bristol Myers Squibb is buying Mirati
Therapeutics in a deal that values the oncology developer at up to
$5.8 billion. The biopharmaceutical company on Sunday said that it
had entered into a definitive merger agreement with Mirati under
which it would pay $58.00 a share in cash. Mirati stockholders will
also receive one non-tradable contingent value right per share,
potentially worth $12.00 a share in cash. Dow Jones & Co. owns
Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
October 09, 2023 10:15 ET (14:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Mirati Therapeutics (NASDAQ:MRTX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Mirati Therapeutics (NASDAQ:MRTX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024